Advanced search
Publication Cover
Future Medicinal Chemistry Volume 14, 2022 - Issue 16
Submit an article Journal homepage
1,304
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Targeting LRRK2 Mutations in Parkinson's Disease

Robert K Leśniak1 Medicinal Chemistry Knowledge CenterSarafan ChEM-HStanford UniversityStanfordCA94305USA;2 Department of Pathology300 Pasteur DriveStanford UniversityStanfordCA94305USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8712-9901
ORCID Icon,
Robert Jeremy Nichols2 Department of Pathology300 Pasteur DriveStanford UniversityStanfordCA94305USA
,
Mark Smith1 Medicinal Chemistry Knowledge CenterSarafan ChEM-HStanford UniversityStanfordCA94305USA
&
Thomas J Montine2 Department of Pathology300 Pasteur DriveStanford UniversityStanfordCA94305USA
Pages 1167-1170 | Received 12 May 2022, Accepted 25 May 2022, Published online: 22 Jun 2022

References

  • Palacios-Sánchez L , TorresNupan M , Botero-MenesesJS. James Parkinson and his essay on “shaking palsy”, two hundred years later. Arq. Neuropsiquiatr.75(9), 671–672 (2017).
  • Kalia LV , LangAE. Parkinson's disease. Lancet386(9996), 896–912 (2015).
  • Marras C , BeckJC , BowerJHet al. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis.4, 21 (2018).
  • Nalls MA , PlagnolV , HernandezDGet al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet377(9766), 641–649 (2011).
  • Nalls MA , BlauwendraatC , VallergaCLet al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol.18(12), 1091–1102 (2019).
  • Zimprich A , BiskupS , LeitnerPet al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron44(4), 601–607 (2004).
  • Paisán-Ruíz C , JainS , EvansEWet al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron44(4), 595–600 (2004).
  • Blauwendraat C , NallsMA , SingletonAB. The genetic architecture of Parkinson's disease. Lancet Neurol.19(2), 170–178 (2020).
  • Jaleel M , NicholsRJ , DeakMet al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J.405(2), 307–317 (2007).
  • Scott JD , DemongDE , GreshockTJet al. Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity. J. Med. Chem.60(7), 2983–2992 (2017).
  • Estrada AA , LiuX , Baker-GlennCet al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem.55(22), 9416–9433 (2012).
  • Andersen MA , ChristensenKV , BadoloLet al. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation. Neurobiol. Dis.116, 13–27 (2018).
  • Fuji RN , FlagellaM , BacaMet al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl. Med.7(273), 273ra215 (2015).
  • ClinicalTrials.gov . Study to Evaluate DNL201 in Subjects With Parkinson's Disease. https://clinicaltrials.gov/ct2/show/study/NCT03710707
  • Liu M , BenderSA , CunyGD , ShermanW , GlicksmanM , RaySS. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. Biochemistry52(10), 1725–1736 (2013).
  • Ray S , BenderS , KangS , LinR , GlicksmanMA , LiuM. The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity. J. Biol. Chem.289(19), 13042–13053 (2014).
  • Williamson DS , SmithGP , Acheson-DossangPet al. Design of leucine-rich repeat kinase 2 (LRRK2) inhibitors using a crystallographic surrogate derived from checkpoint kinase 1 (CHK1). J. Med. Chem.60(21), 8945–8962 (2017).
  • Williamson DS , SmithGP , MikkelsenGKet al. Design and synthesis of pyrrolo [2,3-d]pyrimidine-derived leucine-rich repeat kinase 2 (LRRK2) inhibitors using a checkpoint kinase 1 (CHK1)-derived crystallographic surrogate. J. Med. Chem.64(14), 10312–10332 (2021).
  • Leśniak RK , NicholsRJ , SchonemannMet al. Discovery of G2019S-selective leucine rich repeat protein kinase 2 inhibitors with in vivo efficacy. Eur. J. Med. Chem.229, 114080 (2022).
  • Garofalo AW , BrightJ , DeLombaert Set al. Selective inhibitors of G2019S-LRRK2 kinase activity. J. Med. Chem.63(23), 14821–14839 (2020).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.